The generic version of Vyndamax is expected to be released after 31st August, 2035. This is due to the expiration of the drug's last patent entitled 'Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole' with a US patent number of US9770441.
Vyndamax, containing the active ingredient tafamidis, is used for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM).
Vyndamax holds a total of 3 drug patents. None of these have expired yet with the last one, US9770441, set to expire on 31st August, 2035. This patent is titled 'Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole'. Other patents include US7214696 and US7214695, both titled 'Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding', and expiring on 19th December, 2024. Below are the details of the patent: